Black Hawk Acquisition (BKHA) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Black Hawk Acquisition is the larger company by market cap ($47.9 million vs $46.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | TVGN |
|---|---|---|
| Share price | $11.53 | $7.15 |
| Market cap | $47.89M | $46.56M |
| 1-day change | -6.49% | +1.27% |
| YTD return | — | -57.34% |
| 1-year return | — | -80.50% |
| P/E ratio (TTM) | 34.94 | — |
| EPS (TTM) | $0.33 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $39.00 |
| 52-week low | $11.00 | $3.64 |
| Distance from 52-week high | -12.32% | -81.67% |
| Average volume | 5.83K | 10.03K |
| Shares outstanding | 4.15M | 6.51M |
| Employees | — | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
BKHA vs TVGN FAQ
Which is bigger, Black Hawk Acquisition or Tevogen?
Black Hawk Acquisition (BKHA) is larger, with a market capitalization of $47.89M compared with $46.56M for Tevogen (TVGN).
Are Black Hawk Acquisition and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.